FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Kawakami Mark
2. Date of Event Requiring Statement (Month/Day/Year)
07/05/2024		 3. Issuer Name and Ticker or Trading Symbol
Arcadia Biosciences, Inc. [RKDA]
(Last)
(First)
(Middle)
C/O ARCADIA BIOSCIENCES, INC., 5950 SHERRY LANE, SUITE 215		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Financial Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)

DALLAS, TX 75225		 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 1,281
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 09/13/2031 Common Stock 300 $ 90.8 D  
Stock Option (Right to Buy)   (2) 04/11/2032 Common Stock 300 $ 50.8 D  
Stock Option (Right to Buy)   (3) 08/16/2032 Common Stock 137 $ 37.74 D  
Stock Option (Right to Buy)   (4) 01/01/2033 Common Stock 250 $ 10.8 D  
Stock Option (Right to Buy)   (5) 05/17/2033 Common Stock 500 $ 4.68 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kawakami Mark
C/O ARCADIA BIOSCIENCES, INC.
5950 SHERRY LANE, SUITE 215
DALLAS, TX 75225		       Chief Financial Officer  

Signatures

Mark Kawakami, by Attorney-in-fact, Solaeta Chan 07/18/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The options were granted on 9/13/21 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.
(2) The options were granted on 4/11/22 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.
(3) The options will vest annually in equal installments over a period of three years from the date of the grant, 8/16/2022, subject to the Participant's continued service.
(4) The options were granted on 1/1/23 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.
(5) The options were granted on 5/17/23 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.